Reporter brief
Preoperative SGLT2 inhibitors associated with lower mortality after cardiac procedures in propensity-matched cohort.
What happened
This retrospective cohort study of 15,052 patients (7,526 matched pairs) undergoing major cardiac procedures compared preoperative SGLT2 inhibitor users to non-users. SGLT2 inhibitor use was associated with reduced all-cause mortality at 30 days (1.3% vs 2.3%, RR 0.566), 90 days (2.2% vs 3.4%, RR 0.643), and 1 year (3.8% vs 5.8%, RR 0.657), and with lower acute kidney injury at 30 days (15.4% vs 17.7%, RR 0.870), but higher hospital readmission rates (76.4% vs 68.7%, RR 1.111).
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Cohort; Human.
Adults (≥18 years) undergoing cardiac procedures, identified from the TriNetX U.S. Collaborative Network. Propensity score-matched cohorts with mean age 65.8 ± 10.6 years, 70.5% male, 29.5% female.
- Design
- Cohort
- Sample
- 15,052
- Journal
- Journal of clinical medicine
- Published
- Sep 2, 2026
Effect size
All-cause mortality at 30 days: RR 0.566 [95% CI 0.443-0.722]; at 90 days: RR 0.643 [95% CI not fully specified]; at 1 year: RR 0.657 [95% CI not fully specified]. Acute kidney injury at 30 days: RR 0.870 [95% CI not fully specified]. Hospital admission rates: RR 1.111 [95% CI 1.089-1.133].
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not reported. · Not reported.
Previous evidence
See the SGLT2 inhibitors timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.